» Articles » PMID: 16522905

Soy-isoflavone-enriched Foods and Markers of Lipid and Glucose Metabolism in Postmenopausal Women: Interactions with Genotype and Equol Production

Abstract

Background: The hypocholesterolemic effects of soy foods are well established, and it has been suggested that isoflavones are responsible for this effect. However, beneficial effects of isolated isoflavones on lipid biomarkers of cardiovascular disease risk have not yet been shown.

Objective: The objective was to investigate the effects of isolated soy isoflavones on metabolic biomarkers of cardiovascular disease risk, including plasma total, HDL, and LDL cholesterol; triacylglycerols; lipoprotein(a); the percentage of small dense LDL; glucose; nonesterified fatty acids; insulin; and the homeostasis model assessment of insulin resistance. Differences with respect to single nucleotide polymorphisms in selected genes [ie, estrogen receptor alpha (XbaI and PvuII), estrogen receptor beta (AluI), and estrogen receptor beta(cx) (Tsp509I), endothelial nitric oxide synthase (Glu298Asp), apolipoprotein E (Apo E2, E3, and E4), cholesteryl ester transfer protein (TaqIB), and leptin receptor (Gln223Arg)] and with respect to equol production were investigated.

Design: Healthy postmenopausal women (n = 117) participated in a randomized, double-blind, placebo-controlled, crossover dietary intervention trial. Isoflavone-enriched (genistein-to-daidzein ratio of 2:1; 50 mg/d) or placebo cereal bars were consumed for 8 wk, with a wash-out period of 8 wk before the crossover.

Results: Isoflavones did not have a significant beneficial effect on plasma concentrations of lipids, glucose, or insulin. A significant difference between the responses of HDL cholesterol to isoflavones and to placebo was found with estrogen receptor beta(cx) Tsp509I genotype AA, but not GG or GA.

Conclusions: Isoflavone supplementation, when provided in the form and dose used in this study, had no effect on lipid or other metabolic biomarkers of cardiovascular disease risk in postmenopausal women but may increase HDL cholesterol in an estrogen receptor beta gene-polymorphic subgroup.

Citing Articles

Personalizing Dietary Polyphenols for Health Maintenance and Disease Management: A Nutrigenetic Approach.

Ramos-Lopez O Curr Nutr Rep. 2025; 14(1):29.

PMID: 39907890 DOI: 10.1007/s13668-025-00620-9.


A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity.

Chhabria S, Mathur S, Vadakan S, Sahoo D, Mishra P, Paital B Front Endocrinol (Lausanne). 2022; 13:1027237.

PMID: 36440220 PMC: 9691845. DOI: 10.3389/fendo.2022.1027237.


Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.

Vekic J, Zeljkovic A, Stefanovic A, Bogavac-Stanojevic N, Ilias I, Silva-Nunes J Pharmaceutics. 2022; 14(4).

PMID: 35456658 PMC: 9027611. DOI: 10.3390/pharmaceutics14040825.


A Nutrigenetic Update on CETP Gene-Diet Interactions on Lipid-Related Outcomes.

Wuni R, Kuhnle G, Wynn-Jones A, Vimaleswaran K Curr Atheroscler Rep. 2022; 24(2):119-132.

PMID: 35098451 PMC: 8924099. DOI: 10.1007/s11883-022-00987-y.


Effect of the HXBM408 bacteria on rat intestinal bacterial diversity and the metabolism of soybean isoflavones.

Xiaobin L, Jinglong X, Fang Z, Chenchen W, Kailun Y PLoS One. 2021; 16(7):e0253728.

PMID: 34264976 PMC: 8282076. DOI: 10.1371/journal.pone.0253728.